CD38 positive

P2, N=28, Recruiting, Fondazione Italiana Linfomi - ETS | Trial completion date: Jun 2024 --> Jan 2025 | Trial primary completion date: Jun 2024 --> Jan 2025

We recently reported that increased expression of ST3GAL1 was associated with inferior PFS in patients with autologous stem-cell transplant (ASCT)-eligible newly diagnosed MM patients treated with bortezomib, thalidomide, and dexamethasone (VTd) +/- Dara as induction and consolidation within the CASSIOPEIA study. Conclusions : Within part 2 of CASSIOPEIA, increased expression of ST3GAL1 is significantly associated with inferior PFS and predicts lack of sustained MRD and disease progression in patients MRD negative (10-5) prior to the onset of maintenance therapy or observation. Our preliminary data suggest that desialylation strategies, currently in clinical development, could help achieve deep and durable remissions in MM patients receiving current Dara based quadruplet treatment approaches.

P3, N=650, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Oct 2025 --> Feb 2026

P2, N=82, Active, not recruiting, French Innovative Leukemia Organisation | Recruiting --> Active, not recruiting | Trial completion date: Feb 2028 --> Apr 2030

P1, N=30, Recruiting, Y-mAbs Therapeutics | Not yet recruiting --> Recruiting

Accordingly, this case died of pneumonia with septic shock during treatment. Our findings suggest that the presence of rhomboid crystals in bone marrow smears may alert pathologists to look for the possibility of crystal-storing histiocytosis and the prognosis of patients with multiple myeloma may depend on the genetic features of tumor cells rather than the association with crystal-storing histiocytosis.

The FC analysis of the peripheral blood allowed the rapid characterization of a non-hematological neoplastic cell population, circulating at unusually high frequency and mimicking an acute myeloid leukemia. The FC detection of CD45-negative cell populations in peripheral blood, bone marrow or lymph node aspirate should prompt the setup of an immunophenotyping panel including EpCAM, CD9, CD56 and CD117, to allow for a rapid and accurate identification of ectopic malignant epithelial cells.

P1, N=0, Withdrawn, Jonsson Comprehensive Cancer Center | N=30 --> 0 | Not yet recruiting --> Withdrawn

P1, N=30, Recruiting, Peking University First Hospital

P1/2, N=37, Recruiting, University of Texas Southwestern Medical Center | Not yet recruiting --> Recruiting

P1, N=16, Recruiting, Technische Universität Dresden | Not yet recruiting --> Recruiting

P1, N=30, Not yet recruiting, Y-mAbs Therapeutics | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027

Patients with poor cytogenetic risk were associated with significantly shorter median overall survival when compared to favorable and intermediate cytogenetic risk (p =0.010). The expression of CD38 significantly adds to the prognostic value of cytogenetic risk stratification at diagnosis of AML patients.

This study indicated biological significance of rs1130169 variations that can alter differences in CRC risk by regulating CD38 gene expression.

The in vitro findings indicated that the anti-CD38 CAR-NK cells have the potential to be used as an off-the-shelf therapeutic strategy against CD38-positive malignancies. It is recommended that the present engineered NK cells undergo additional preclinical investigations before they can be considered for subsequent clinical trial studies.

P1, N=30, Not yet recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Dec 2027 --> Mar 2028 | Initiation date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2026 --> Mar 2027

Peptide probes were labeled with indocyanine green (ICG) dye and Ga-DOTA, which were injected into a CD38-positive Ramos tumor-bearing mouse via its tail vein, and small animal fluorescence and positron emission tomography (PET) imaging showed that the peptide probes could show specific enrichment in the tumor tissue. Our study shows that a microchip-based screening of peptide probes can be used as a promising imaging tool for MM diagnosis.

Treatment with AZD3965 improved the phenotype of moDCs co-cultured with MM cells, reversing their suppressive effect on T-cell proliferation... Patients with MM exhibit a reduced frequency of cDC1 subsets, which are crucial for cross-presentation to CD8 + T cells. moDCs in acid pH conditions derived from MM cells display an immature phenotype and impaired function due to decreased DC activation signals. Furthermore, inflammasome activation promotes the secretion of IL-1β and IL-18, contributing to pro-tumorigenic inflammation in the MM microenvironment.

Given innate fragility and higher chemo sensitivity in patients with DS, we elected to treat him off protocol with Cladribine and low dose Ara-C alternating with Decitabine. AML treatment in DS remains a challenge and further research is warranted to develop tailored regimens effectively balancing curative intent and reduced toxicity. This regimen could be considered in pediatric patients with Down Syndrome and other comorbidities.

Surprisingly, the clonal mutations were not well mixed in the BM with regions of high clonal diversity millimeters away from regions with a paucity of these mutated clones. Future work will expand this platform to describe BM clonal architecture in a larger set of bone marrow specimens and a wide variety clinical scenarios to help further explain the role of the BM niche in CH, MPNs and leukemia.

The flow cytometric analysis allowed to discover the non-hematological nature of this population, circulating at high level in peripheral blood. Aspirate smears revealed the presence of the same cells, and immunohistochemistry on bone marrow confirmed the massive infiltration of breast cancer cells, allowing to diagnose bone marrow metastases.

This report showcases a rare age presentation with unique manifestations of secondary plasma cell leukaemia. Multiple myeloma should be a differential diagnosis for cases with unexplained back pain despite an unclassical age.

He received one cycle of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone), followed by seven cycles of KCD (Carfilzomib, Cyclophosphamide, Dexamethasone) and Rituximab...The patient was treated with Acalabrutinib, and his anemia, epistaxis, and coagulopathy resolved...In contrast to our patient, who has LPL with IgG Monoclonal gammopathy, approximately 95 percent of LPL patients have IgM Monoclonal gammopathy, which corresponds with WM. As a result, clinicians should be on the lookout for LPL that lacks an IgM Monoclonal Paraprotein.

The observed co-localization of the different immune subsets following vaccination supports the hypothesis of local antigen capturing by blood derived and local antigen presenting cells (Zuo et al, 2021). The local immune response may ultimately leads to a systemic immune response and disease control.

P1, N=16, Not yet recruiting, Technische Universität Dresden | Initiation date: Jul 2023 --> Dec 2023

P2, N=30, Recruiting, Carl Ola Landgren, MD, PhD | Not yet recruiting --> Recruiting | Trial completion date: Mar 2030 --> Dec 2030 | Trial primary completion date: Mar 2028 --> Dec 2028

A favorable prognostic significance of tumor-infiltrating plasma cells could be demonstrated in triple-negative breast cancer immunohistochemically analyzed for the CD38 and IgκC expression. CD38 was identified as an independent prognostic factor via multivariate Cox regression.

This bispecific antibody targets unique epitopes on CD38 and ICAM-1 on tumor cells with reduced red blood cell binding compared to the benchmark CD38 antibody daratumumab. Interestingly, combination of VP301 with the immunomodulatory drug, lenalidomide, led to synergistic anti-tumor growth activity in an in vivo efficacy study. In conclusion, the CD38 x ICAM-1 bispecific antibody VP301 demonstrated promising efficacy and specificity toward CD38+ and ICAM-1+ tumor cells and represents a novel approach for treating multiple myeloma and lymphoma.

P1, N=23, Completed, Emory University | Active, not recruiting --> Completed | Trial completion date: May 2024 --> Oct 2022 | Trial primary completion date: May 2024 --> Oct 2022

In the largest to date single-cell RNA-sequencing study of immune cells from patients with monoclonal gammopathies, we have comprehensively mapped alterations in BM immune cell composition in patients with MGUS, identified subpopulations that are more likely to interact directly with tumor cells in the BM microenvironment, and described immune hallmarks of disease.

The patient was diagnosed with lymphoplasmacytic lymphoma based on cell morphology and CD20-positivity and was treated with five cycles of a bendamustine-rituximab regimen for 17 months. Small cell-variant plasma cell myeloma could be misdiagnosed as other mature B-cell neoplasms owing to its small lymphocyte-like morphology, frequent CD20-positivity, and frequent light chain type that lacks a rouleaux formation. Flow cytometric immunophenotyping and IHC for CD45 and CD138 may assist in the differential diagnosis.

PD-1–positive TFH cell proliferation, although not specific, is a feature associated with peripheral T-cell lymphomas of TFH cell derivation, which increases diagnostic difficulties for MZL. Next-generation sequencing for lymphoma panel shows a pathogenic variant of TNFSRF14 C.215 G>A that has been reported in diffused large B-cell lymphoma but not in nodal MZL with plasmacytic differentiation.

CTS may be an early sign of systemic amyloidosis. Congo red stain should be performed on tenosynovial tissue at the time of carpal tunnel release surgery.

We report the case of a 70-year-old man with IgA lambda multiple myeloma treated with daratumumab, cyclophosphamide, bortezomib, dexamethasone (DaraCyBorD) and carfilzomib, pomalidomide, dexamethasone (KPomD) who presented with altered mental status and severe generalized weakness. Histology in such cases shows sinusoidal flooding by neoplastic plasma cells with little or no propensity to destroy the underlying liver parenchyma. Radiographic imaging is usually unable to detect this diffuse infiltrative pattern; therefore, a liver biopsy is essential to make a diagnosis.

Bilateral pleural catheters were placed, and the patient was discharged on daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) with a plan for autologous stem cell transplant. It is important to keep a broad differential for a patient presenting with pleural effusions. As EMD in MM can have variable presentations, recognizing myelomatous pleural effusions early is required to start appropriate therapy to treat the underlying cause.

She was immediately started on palliative radiation therapy and chemotherapy with carfilzomib, daratumumab and dexamethasone. Our patient presented with dysphagia, dyspnea, and chest pressure due to mass effect on the trachea and esophagus. Due to critical central airway obstruction, rapid diagnosis and treatment is imperative. Treatment for with appropriate chemotherapy can cause quick resolution of tumor.

P3, N=590, Recruiting, Janssen Research & Development, LLC | Trial completion date: May 2032 --> Aug 2031

P1, N=30, Not yet recruiting, Jonsson Comprehensive Cancer Center

OBSERVATIONS: A 72 years-old woman, with history of liver transplantation because of primary biliary cirrhosis in 1996, on treatment with meprednisone 4 mg and cyclosporine 100 mg, developed multiple tumoral exofitic lesions, the biggest of about 20x15 cm, on the external side of the left leg, and smaller lesions on the internal side...Skin involvement of PBL was diagnosed and immunosuppressive therapy was switched to sirolimus...Despite one year of treatment with entecavir, viral load was still positive, so antiviral therapy was switched to tenofovir. After three years of follow up and without antineoplastic treatment, the patient has no evidence of disease. KEY MESSAGE: The importance to present a case of an infrequent and aggressive monomorphic PTLD after 25 years of liver transplantation, with regression after reduction of the immunosuppression.

P3, N=590, Recruiting, Janssen Research & Development, LLC | Trial completion date: Aug 2031 --> May 2032